R&D PIPELINE THERAPY AREAS

R&D Pipeline Therapy Areas

The agents and uses mentioned below are investigational and have not been approved by the US Food and Drug Administration (FDA) for the uses under investigation. No conclusions regarding safety and efficacy should be drawn for such agents and uses.
Sanofi is investigating new molecular entities as well as expanded indications for current approved products for a variety of type 2 inflammatory diseases, including chronic spontaneous urticaria and chronic obstructive pulmonary disease, among others. Expanded indications for a current approved product are also under investigation for polyarticular juvenile idiopathic arthritis and systemic juvenile arthritis.

Latest News from Sanofi

Sanofi Presents New data at ERS across a variety of respiratory conditions
Positive Topline phase 2b data in atopic dermatitis support amlitelimab as a potential first in class novel investigational anti-OX40-ligand monoclonal antibody

Educational Resources

General

Pre-approval Information Exchange: Overview of the Sanofi Specialty Care Pipeline
A presentation providing a brief general overview of Sanofi’s specialty care R&D pipeline, including investigational agents and proposed mechanistic targets in AD, chronic spontaneous urticaria, asthma, and chronic obstructive pulmonary disease. All information is updated quarterly.

Chronic Spontaneous Urticaria

Current Understanding and Disease Management of Chronic Spontaneous Urticaria
A resource discussing clinical features, epidemiology, disease burden, pathophysiology, and disease management of Chronic Spontaneous Urticaria.

Dupilumab Chronic Spontaneous Urticaria Phase 3 CUPID Data
A presentation providing an overview of the dupilumab clinical development program in chronic spontaneous urticaria: the Phase 3 LIBERTY-CSU CUPID study. The presentation includes the study design and topline results.

LIBERTY-CSU CUPID: NCT04180488